The Biden Administration announced in September that the federal government has run out of funding to keep providing free COVID-19 vaccines and that, absent further Congressional action, it is preparing to transition vaccines to the commercial market. That move, according to a new Kaiser Family Foundation (KFF) analysis, could increase spending on COVID-19 vaccines by billions of dollars per year.

"Manufacturers will be negotiating prices directly with insurers and purchasers, not just the federal government, and prices are expected to rise," according to the Dec. 7 report, titled "How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?"

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.